Skip to content

Clinical study of the ability of celecoxib combined with olanzapine and paroxetine hydrochloride to improve depression,anxiety and analgesic effects in patients after hemorrhoidal surgery

Clinical study of the ability of celecoxib combined with olanzapine and paroxetine hydrochloride to improve depression, anxiety and analgesic effects in patients after hemorrhoidal surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112052
Enrollment
Unknown
Registered
2025-11-10
Start date
2023-01-10
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Interventions

Experimental group:under the guidance of a psychologist, the patient received olanzapine 5 mg/qn+ paroxetine hydrochloride 20 mg/qd orally from the day of admission and olanzapine 5 mg and celecoxib 0
Control group:patients did not receive any oral drugs at admission and received 0.2 g of celecoxib orally the night after surgery and 0.2 g/bid of celecoxib from the first day after surgery to dischar

Sponsors

Affiliated Hospital of Jining Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18 and 70 years old, 2. Routine blood test, blood coagulation test, liver and kidney function, blood lipid and blood glucose, six and three hepatitis antibodies, electrocardiogram and chest X-ray were all within the normal range. 3. No history of mental illness, normal communication and understanding ability.

Exclusion criteria

Exclusion criteria: 1. Preoperative history of other comorbidities and other systemic diseases or surgery, including Crohn's disease; 2. Pregnant or lactating women; 3. Hemorrhoids complicated with complex anal fistula or perianal abscess; 4. Male prostate disease and other lesions with increased abdominal pressure; 5. Repeated hemorrhoids resection and recurrent hemorrhoids; 6. Patients who had taken antidepressant drugs before treatment; 7. Patients with other types of mental disorders; 8, cardiovascular and cerebrovascular, liver and kidney function, lung function, hematopoietic function, nerve function and other important organs of the body serious lesions; 9. Patients who had taken medication for chronic pain for a long time.

Design outcomes

Primary

MeasureTime frame
Visual analog scale (VAS) score;Self-rating anxiety scale (SAS) score;Self-rating depression scale (SDS) score;

Secondary

MeasureTime frame
Analgesic effect;Sleep quality;Urination condition;

Countries

China

Contacts

Public ContactShubo Gao

Affiliated Hospital of Jining Medical University

33820214@qq.com+86 175 5370 5058

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026